Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEDO-PREDIRESP: Vedolizumab Pharmacokinetics in Crohn's Disease
NCT02768532Phase 4Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Jul 2016
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vedolizumab in Crohn's disease, sponsored by CHU Saint-Etienne. Started Jul 2016; status: terminated.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02768532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768532.